| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
||
| 424B4 | Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 |
Registration Statements
|
||
| S-1MEF | Registration of up to an additional 20% of securities for any offering registered on an S-1 |
Registration Statements
|
||
| EFFECT | EFFECT |
Other
|
||
| CORRESP | CORRESP |
Other
|
||
| CORRESP | CORRESP |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
